Advancing KRAS G12C-Targeted Therapies in NSCLC: Current Evidence and Future Directions

episode

Previously titled “Advancing KRAS [LD1.1]G12C-Targeted Therapies in NSCLC: Current Evidence and Future Directions” — renamed by the publisher on Aug 4, 2026

Decera Clinical Education Oncology Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

recent transcribed audio

A.I. Safety Goes Mainstream + a ‘Hard Fork’ Exit AMA 1h 25m · 18 Sep 2026 · Hard Fork

Layoffs at the Kansas City Star will hurt local communities 15 min · 18 Sep 2026 · Kansas City Today

AWP: Beyond the Exam Room: Purpose, Myopia, and Population Health 54 min · 17 Sep 2026 · EyeCode Media

Planning Commission Meeting - Sep 17, 2026 1h 11m · 17 Sep 2026 · Leesburg Planning Commission

Heritage Commission - Sep 14, 2026 1h 57m · 17 Sep 2026 · Loudoun County Board Committees and Advisory Boards

Historic District Review Committee - Sep 14, 2026 1h 36m · 17 Sep 2026 · Loudoun County Board Committees and Advisory Boards

Report any issue

Source

Recorded09 Mar 2026

Publisherfeeds.simplecast.com ↗

Handlerec:16822013

Show notes

In this episode, Dr Paz-Ares and Dr Christine Bestvina discuss the evolving role of KRAS G12C inhibitors in non-small-cell lung cancer (NSCLC), including: Clinical outcomes and limitations of first-generation KRAS G12C inhibitors Key unmet needs, including primary and acquired resistance Emerging strategies, including next-generation inhibitors and combination approaches with chemotherapy and immunotherapy Presenters: Luis Paz-Ares, MD, PhD Head of Medical Oncology Department Hospital Universitario 12 de Octubre Associate Professor, Universidad Complutense de Madrid Madrid, Spain Christine Bestvina, MD Associate Professor University of Chicago Medicine Division of Medicine Section of Hematology/Oncology University of Chicago Medicine Chicago, IllinoisLink to full program:https://bit.ly/4rhoUuN Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related